Bavarian Nordic sells its Priority Review Voucher for $160M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 18 2025
0mins
Source: SeekingAlpha
Bavarian Nordic's PRV Sale: Bavarian Nordic is selling its Priority Review Voucher for $160 million, which was awarded after the FDA approved its chikungunya vaccine, VIMKUNYA. The National Institutes of Health will receive 20% of the sale proceeds.
Financial Impact and Review: The sale will be recorded as other operating income, positively affecting EBITDA, while the transaction is subject to an antitrust review expected in Q3 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
